“The trial did not achieve the main goal of preventing symptomatic Covid-19 cases after exposure” to the virus, explains the laboratory in a communicated, noting that the participants in this trial were unvaccinated adults over the age of 18, who had been exposed to an infected person during the previous eight days.
AZD7442 treatment only reduced the risk of developing symptomatic Covid-19 by 33%, which was not statistically significant, according to AstraZeneca.
“Although this trial did not meet the primary endpoint against symptomatic disease, we are encouraged by the protection observed in participants negative to a PCR test after treatment with AZD7442”, further specifies the vice -Executive Chairman of AstraZeneca, Mene Pangalos.
AstraZeneca is also studying the treatment in a trial on pre-exposed patients and for the prevention of more serious disease. Trials are also continuing to assess the effect of this product on patients before their exposure to the virus as well as on those who have developed severe forms.
Vaccine effective against the new Delta variant
Despite the controversy surrounding the Anglo-Swedish laboratory regarding its potential links with very serious side effects that have appeared in some people who had received it, the company has confirmed the effectiveness of its anti-Covid-19 vaccine against the new Delta variant , first discovered in India.
According to an analysis published by the British health organization Public Health England (PHE), the two doses of the anti-Covid-19 vaccine developed by AstraZeneca in partnership with the University of Oxford offer protection from more than 90% against the risk of hospitalization after contamination by the Indian variant.
(With MAP)
–
